Valuation: Celldex Therapeutics, Inc.

Market Cap 2.77B 2.43B 2.26B 2.08B 3.9B 267B 3.96B 26.82B 10.49B 131B 10.39B 10.17B 453B P/E 2026 *
-8.13x
P/E 2027 * -8.13x
Enterprise Value 2.19B 1.92B 1.78B 1.64B 3.08B 211B 3.13B 21.16B 8.28B 103B 8.2B 8.03B 358B EV / Sales 2026 *
904x
EV / Sales 2027 * 204x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celldex Therapeutics, Inc.

Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 29/07/2014
Chief Executive Officer 64 31/08/2008
Director of Finance/CFO 55 31/03/2009
Director TitleAgeSince
Director/Board Member 64 30/11/2008
Chairman 80 04/06/2025
Director/Board Member 93 29/02/2008
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.77B
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+647.65% 40.23B
-0.27%+4.45%+11.81%+60.81% 36.23B
+0.35%+0.87%+4.46%-10.31% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.44% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.10% 13.12B
-2.68%-2.49%-11.36%-34.51% 12.7B
Average +0.22%+0.83%+54.56%+107.32% 27.25B
Weighted average by Cap. +0.48%+0.91%+74.42%+137.69%

Financials

2026 *2027 *
Net sales 2.42M 2.12M 1.97M 1.81M 3.4M 233M 3.46M 23.4M 9.15M 114M 9.07M 8.87M 396M 11.04M 9.7M 9.02M 8.28M 15.56M 1.07B 15.8M 107M 41.83M 522M 41.44M 40.56M 1.81B
Net income -330M -290M -270M -247M -465M -31.87B -472M -3.2B -1.25B -15.62B -1.24B -1.21B -54.03B -367M -323M -300M -275M -518M -35.48B -526M -3.56B -1.39B -17.39B -1.38B -1.35B -60.15B
Net Debt -584M -513M -477M -438M -823M -56.4B -836M -5.66B -2.21B -27.64B -2.19B -2.15B -95.61B -515M -452M -421M -386M -726M -49.73B -737M -4.99B -1.95B -24.37B -1.93B -1.89B -84.31B
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
35.28USD
Average target price
55.47USD
Spread / Average Target
+57.22%

Quarterly revenue - Rate of surprise